Literature DB >> 9189639

The cost of antibiotic resistance--from the perspective of a bacterium.

R E Lenski1.   

Abstract

The possession of an antibiotic resistance gene clearly benefits a bacterium when the corresponding antibiotic is present. But does the resistant bacterium suffer a cost of resistance (i.e. a reduction in fitness) when the antibiotic is absent? If so, then one strategy to control the spread of resistance would be to suspend the use of a particular antibiotic until resistant genotypes declined to low frequency. Numerous studies have indeed shown that resistant genotypes are less fit than their sensitive counterparts in the absence of antibiotic, indicating a cost of resistance. But there is an important caveat: these studies have put antibiotic resistance genes into naïve bacteria, which have no evolutionary history of association with the resistance genes. An important question, therefore, is whether bacteria can overcome the cost of resistance by evolving adaptations that counteract the harmful side-effects of resistance genes. In fact, several experiments have shown that the cost of antibiotic resistance may be substantially diminished, even eliminated, by evolutionary changes in bacteria over rather short periods of time. As a consequence of this adaptation of bacteria to their resistance genes, it becomes increasingly difficult to eliminate resistant genotypes simply by suspending the use of antibiotics.

Entities:  

Mesh:

Year:  1997        PMID: 9189639     DOI: 10.1002/9780470515358.ch9

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  16 in total

1.  Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans.

Authors:  L E Cowen; L M Kohn; J B Anderson
Journal:  J Bacteriol       Date:  2001-05       Impact factor: 3.490

Review 2.  Infection and antimicrobial prescribing control in the new millennium: nightmare or nirvana?

Authors:  B Cookson
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

Review 3.  Mutation frequencies and antibiotic resistance.

Authors:  J L Martinez; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 4.  Stress-induced evolution and the biosafety of genetically modified microorganisms released into the environment.

Authors:  V V Velkov
Journal:  J Biosci       Date:  2001-12       Impact factor: 1.826

5.  Spatial variation in frequency and intensity of antibiotic interactions among Streptomycetes from prairie soil.

Authors:  Anita L Davelos; Linda L Kinkel; Deborah A Samac
Journal:  Appl Environ Microbiol       Date:  2004-02       Impact factor: 4.792

Review 6.  Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

Review 7.  Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents.

Authors:  Julian Gregston Hurdle; Alexander John O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

8.  Phenotypic and genotypic analyses of Neisseria gonorrhoeae isolates that express frequently recovered PorB PIA variable region types suggest that certain P1a porin sequences confer a selective advantage for urogenital tract infection.

Authors:  Lotisha E Garvin; Margaret C Bash; Christine Keys; Douglas M Warner; Sanjay Ram; William M Shafer; Ann E Jerse
Journal:  Infect Immun       Date:  2008-06-09       Impact factor: 3.441

9.  Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models.

Authors:  D J Austin; R M Anderson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-04-29       Impact factor: 6.237

10.  Historical contingency and the evolution of a key innovation in an experimental population of Escherichia coli.

Authors:  Zachary D Blount; Christina Z Borland; Richard E Lenski
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.